United Therapeutics Reports Q2 2026 Revenue of $783.3M, Net Income Up 8% to $333M

UNITED THERAPEUTICS Corp

2026-Q2 EPS reported $13.07 revenue$1,564,800,000

Total revenues decreased 2% year-over-year to $783.3M; net income rose 8% to $333.0M.
Tyvaso DPI revenues grew 4% to $326.6M; Nebulized Tyvaso fell 18% to $126.0M.
Submitted NDAs for ralinepag tablets in PAH and Nebulized Tyvaso in IPF; potential approvals in 2027.
Repurchased ~2.76M shares under $1.5B ASR agreements; $500M remaining in buyback program.
R&D expense increased 9% to $146.3M driven by cardiopulmonary projects and contingent consideration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.